By Turna Ray
As part of its Genetics for Generics program, Medco is planning a comparative effectiveness study of two competing blood-thinning drugs • Bristol-Myers Squibb's soon-to-be off-patent Plavix and Eli Lilly's newer, more expensive Effient • to assess whether it will be clinically useful and cost-effective to genetically test Plavix patients to establish their CYP2C19 status.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.